Company intelligence / Profile preview

Enthorin Therapeutics

Escondido, California, USA

Ownership: Private
Development stage: Other

Overview

Lead program MRM-3379 (ENT-3379), a selective inhibitor of PDE4D, showed favorable brain penetration and safety in Phase 1; Phase 2 trial for Fragile X syndrome is planned by Mirum Pharmaceuticals, which recently acquired rights. No therapies approved yet.

Therapeutic areas: NeurologyCardiovascular
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Dart NeuroScience (originator/developer of lead program)Mirum Pharmaceuticals (global licensee for MRM-3379/ENT-3379)

Beyond the preview

Go deeper on Enthorin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enthorin Therapeutics.